PETALING JAYA: Sunway Healthcare Holdings Bhd is in a solid position for future growth.
The soon-to-be listed private hospital operator’s bottom line is expected to grow by strong double digits ahead of its listing on Bursa Malaysia.
But in the short term, its financial year 2025 (FY25) earnings before interest, taxes, depreciation and amortisation (Ebitda) margins are seen to decline slightly due to the gestation impact of Sunway Medical Centre (SMC) Damansara and SMC Ipoh.
Based on TA Research’s projections, Sunway Healthcare’s FY25 revenue and Ebitda are expected to rise 18.8% and 8.8% to RM2.2bil and RM511mil, respectively.
“The improved performance is expected to be underpinned by stronger demand and increased availability of licensed beds.
“FY25 patient census is anticipated to grow by 8% year-on-year, supported by continued expansion of existing hospitals and the ramp-up of newly opened facilities,” TA Research added.
“We project Sunway Healthcare’s FY26 and FY27 net profit to grow by 32.1% and 34.3%, respectively, driven by stronger operating metrics and improving Ebitda margins.
“In January 2026, SMC Damansara achieved a pre-tax profit breakeven, while SMC Ipoh reached Ebitda breakeven.”
TA Research expects growth to be further supported by rising utilisation rates at existing hospitals, brownfield expansions, higher patient volumes and increased case intensity. It forecasts the FY26 and FY27 Ebitda margins to improve to 24.2% and 27.5%, respectively, from 23.2% in FY25.
